NMOSD vs MS: Why It's Mistaken and How Treatment Differs

Research-informed explainer — last updated April 12, 2026

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease that attacks the optic nerves and spinal cord. For decades it was classified as a severe form of MS, and many patients still receive the wrong diagnosis — which matters enormously because some MS medications can actually make NMOSD worse. The discovery of the AQP4-IgG blood antibody in 2004 changed everything, enabling accurate diagnosis for the first time and opening the door to NMOSD-specific treatments that dramatically reduce relapses.

This explainer draws on published research from five neurologists in the Convene directory. Sean Pittock, M.D., at Mayo Clinic, discovered the AQP4-IgG autoantibody that distinguishes NMO from MS and led the revised diagnostic criteria [1][2][3][4][10]. Brian Weinshenker, M.D., at the University of Virginia, characterized the natural history of the disease and the role of plasma exchange in severe attacks [5][9]. Michael Levy, M.D., Ph.D., at Massachusetts General Hospital, led the Phase 3 PREVENT trial of eculizumab in AQP4-positive NMOSD and the international recommendations on MOG antibody disease [6][7]. Bruce Cree, M.D., at UCSF, published the open-label rituximab study that established B-cell depletion as effective maintenance therapy [8]. David Lynch, M.D., at Children's Hospital of Philadelphia, contributed foundational work on anti-NMDA receptor encephalitis, an important condition to rule out when NMOSD presents atypically [11].

What is the difference?

MS and NMOSD are both inflammatory demyelinating conditions — they both damage myelin, the insulating sheath around nerve fibers — but they have different biological causes, different imaging patterns, and different preferred treatments. MS is driven primarily by T cells and involves scattered lesions across the brain and spinal cord. NMOSD, in most patients, is driven by IgG antibodies that target the aquaporin-4 (AQP4) water channel, which is concentrated in the optic nerves and spinal cord. The result is that NMOSD attacks tend to be more severe and more focused than typical MS relapses, and the risk of permanent disability from each attack is higher.

At a glance

When each diagnosis applies

NMOSD is confirmed when a patient has optic neuritis, a transverse myelitis with a spinal cord lesion spanning three or more vertebral segments (called a longitudinally extensive transverse myelitis, or LETM), or other characteristic features, combined with a positive AQP4-IgG blood test. The 2006 revised criteria established that brain involvement does not rule out NMOSD — a point that caused significant diagnostic confusion before the antibody test was available [2][10].

MS diagnosis requires evidence of CNS lesions disseminated in both space and time, following the McDonald criteria (most recently revised in 2017 by an international panel that included several Convene providers). MS lesions are typically short — one or two vertebral segments — while NMO lesions span three or more segments. This spinal cord MRI distinction is one of the most reliable ways to distinguish the conditions before antibody results are available.

About 20 percent of NMOSD patients are AQP4-IgG-negative. Some of these patients have antibodies to myelin oligodendrocyte glycoprotein (MOG-IgG) and are classified as MOG antibody-associated disease (MOGAD), which has its own distinct clinical features and treatment implications [7].

What the research showed

The breakthrough came in 2004, when Pittock and colleagues at Mayo Clinic identified a serum IgG autoantibody that was present in 73 percent of NMO patients and absent in MS patients [1]. The following year, the target antigen was identified as aquaporin-4, a water channel protein highly expressed in astrocytic end-feet at the blood-brain barrier [3]. This explained why NMO attacks target the optic nerves and spinal cord so specifically — those regions have the highest AQP4 density in the CNS.

The natural history study by Weinshenker and colleagues, published in 1999, followed 71 NMO patients and found that 55 percent of relapsing-onset NMO patients had significant visual or motor disability within five years. Many patients had incomplete recovery from each attack. This pattern differs from typical relapsing-remitting MS, where full recovery between attacks is more common [5].

For treatment, the Phase 3 PREVENT trial enrolled 143 AQP4-IgG-positive NMOSD patients and found that eculizumab, a complement inhibitor given by IV infusion every two weeks, reduced the risk of relapse by 94 percent versus placebo. Of the 96 patients on eculizumab, only 3 had a relapse during the trial, compared with 20 of 47 patients on placebo [6]. Eculizumab became the first FDA-approved treatment specifically for NMOSD in 2019.

For maintenance therapy before eculizumab, rituximab — which depletes CD20-positive B cells — was studied in an open-label study of 8 NMO patients. Six of eight were relapse-free after rituximab, and the median attack rate fell from 2.6 per year before treatment to zero per year during follow-up [8]. Plasma exchange has also been shown to be effective for acute severe attacks that do not respond to high-dose steroids [9].

Why MS drugs can harm NMOSD patients

This is the most dangerous consequence of misdiagnosis. Interferon beta, natalizumab, and fingolimod — all effective MS therapies — have been reported to cause clinical worsening or rebound attacks in AQP4-positive NMOSD patients. The mechanisms vary: interferon beta may promote the autoimmune B-cell response that drives NMO; natalizumab may allow immune cells to accumulate outside the CNS when the drug is stopped; fingolimod may trigger rebound inflammation in NMO. These are not hypothetical risks — they have been observed in clinical reports and case series. This is why getting the AQP4-IgG test before starting any treatment is essential when NMOSD is on the differential.

What is changing

Three additional FDA-approved therapies now exist for AQP4-positive NMOSD: inebilizumab (Uplizna), which targets CD19 and provides broader B-cell depletion than rituximab; satralizumab (Enspryng), an IL-6 receptor inhibitor that can be self-injected; and rozanolixizumab (Rystiggo), approved in 2023. For MOG-IgG-positive disease, standard immunosuppressants like azathioprine and mycophenolate mofetil remain common, with inebilizumab showing promise in ongoing trials.

Questions to ask your doctor

• Have I been tested for AQP4-IgG? If my result was negative, was MOG-IgG also tested?
• Does my spinal cord MRI show lesions spanning three or more segments? How does that affect my diagnosis?
• If I have NMOSD, should I avoid interferon beta, natalizumab, or fingolimod?
• Is eculizumab or one of the newer approved biologics right for my situation, or would rituximab or azathioprine be a reasonable option?
• How often should I expect attacks if I stay on maintenance therapy, versus without treatment?
• Is there a clinical trial I should know about for my antibody status?

The bottom line

NMOSD and MS look similar at first glance — both cause optic neuritis, weakness, and spinal cord problems — but they are biologically distinct diseases that require different treatment strategies. A simple blood test for AQP4-IgG can usually distinguish them. Getting that test before starting any MS treatment is not optional: the wrong therapy can cause the disease to worsen. If you have had a severe optic neuritis or transverse myelitis with a long spinal cord lesion, ask specifically about NMOSD antibody testing before proceeding with treatment.